AT-Patch (ATP-C130/ATP-C70) vs EchoNext

AT-Patch is a wearable, lightweight (13g), shower-proof device that offers up to 14 days of continuous monitoring without needing recharging or electrode replacement, promoting high patient adherence and comfort during daily activities. It also features a smartphone app (AT-Note) for live ECG viewing and symptom recording, and its analysis software (AT-Report) is designed for rapid and elaborate analysis by medical professionals. EchoNext, while utilizing standard ECGs which are routine and inexpensive, is a software tool deployed through a clinical decision support platform, meaning its usability is more focused on the clinician's workflow rather than direct patient interaction and comfort.

EchoNext offers significant clinical value by detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs, which traditionally cannot identify these conditions. Studies have shown EchoNext to have high diagnostic accuracy, outperforming cardiologists in identifying structural heart problems. AT-Patch provides continuous ECG monitoring for arrhythmia detection, which is crucial for conditions like atrial fibrillation, and has demonstrated comparable diagnostic capability to conventional systems.

EchoNext has publicly available tiered pricing starting at $600/month, offering transparency and different options for various institutional sizes, including discounts for annual commitments. This clear pricing structure allows potential customers to assess the cost-effectiveness directly. AT-Patch's pricing is not publicly available and typically involves direct sales, making it difficult to assess its value proposition without direct inquiry.

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians, indicating a strong existing infrastructure for deployment and integration into clinical workflows. It also explicitly mentions being designed for broad access, from major hospitals to community practices, and has secured significant seed funding to support expansion across health systems. AT-Patch's deployment is on-premise at medical institutions, and while it has FDA clearance and is used in clinical studies, its enterprise readiness details are less explicitly defined in terms of broad platform integration or scalability across diverse healthcare settings.

EchoNext represents a significant innovation by being the world's first FDA-approved AI tool to detect hidden structural heart disease from standard ECGs, a capability previously not thought possible with ECGs alone. This expands the utility of a common, inexpensive test for early detection of serious conditions. AT-Patch offers innovative features like a shower-proof design, long-term continuous monitoring without charging, and AI-powered arrhythmia analysis, but its core function of ECG monitoring is a more established area.

Both tools are FDA-cleared, implying a certain level of documentation and validation. AT-Patch provides a smartphone app (AT-Note) for patients and analysis software (AT-Report) for clinicians, with user manuals available. EchoNext has been developed by researchers at NewYork-Presbyterian and Columbia University, with studies published in reputable journals like Nature and Nature Medicine, suggesting robust scientific documentation. However, specific details on ongoing customer support channels, training programs, or publicly accessible comprehensive documentation portals are not extensively detailed for either product in the provided information.